Targeted Therapies

  • Author: Gail Wilkes, RNC, ANP-BC, MS, AOCN® (More Info)
  • Section Editor: Marlene SanFilippo, MSN, ARNP, FNP-C, AOCNP®
  • Editors In Chief: Dawn Camp-Sorrell, MSN, FNP, AOCN®; Rebecca Hawkins, MSN, ANP, AOCN®, ACHPN
  • Last Reviewed: 5/26/17 (What's New)


  • Bruton’s tyrosine kinase, or BTK, is a new target for therapy of B-cell malignancies with ibrutinib first in class (Table 21)
  • Most commonly occurring side effects are pancytopenia, GI complications, musculoskeletal pain, peripheral edema, and rash

Action required